{"id":1320,"date":"2019-08-20T16:37:46","date_gmt":"2019-08-20T16:37:46","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1320"},"modified":"2026-02-24T00:32:22","modified_gmt":"2026-02-24T00:32:22","slug":"addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/","title":{"rendered":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman)"},"content":{"rendered":"<p>At this moment, risk management for non-BRCA1\/2 breast cancer families is mainly based on family history, calculated by risk prediction algorithms such as BOADICEA. Here, we use a Polygenic Risk Score based on 161 breast cancer associated SNPs, to show the potential clinical utility of this PRS within non-BRCA1\/2 high risk breast cancer families including both breast cancer cases and their healthy female relatives. We found that the PRS was significantly associated with breast cancer within these families. In addition, the PRS may change breast screening recommendations in up to 20% of the women from these families, depending on screening guideline thresholds. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2019\/06\/11\/jmedgenet-2019-106072\">https:\/\/jmg.bmj.com\/content\/early\/2019\/06\/11\/jmedgenet-2019-106072<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/picture-for-jmg-blog-manuscript-id-jmedgenet-2019-106072-r1\/\" rel=\"attachment wp-att-1321\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1321\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png\" alt=\"\" width=\"300\" height=\"244\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png 300w, https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--768x624.png 768w, https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--640x520.png 640w, https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png 1004w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>At this moment, risk management for non-BRCA1\/2 breast cancer families is mainly based on family history, calculated by risk prediction algorithms such as BOADICEA. Here, we use a Polygenic Risk Score based on 161 breast cancer associated SNPs, to show the potential clinical utility of this PRS within non-BRCA1\/2 high risk breast cancer families including [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1320","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"At this moment, risk management for non-BRCA1\/2 breast cancer families is mainly based on family history, calculated by risk prediction algorithms such as BOADICEA. Here, we use a Polygenic Risk Score based on 161 breast cancer associated SNPs, to show the potential clinical utility of this PRS within non-BRCA1\/2 high risk breast cancer families including [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-20T16:37:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T00:32:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1004\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\\\/2 breast cancer families (Contributed by Ms. Inge Lakeman)\",\"datePublished\":\"2019-08-20T16:37:46+00:00\",\"dateModified\":\"2026-02-24T00:32:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/\"},\"wordCount\":134,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2019\\\/08\\\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/\",\"name\":\"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\\\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2019\\\/08\\\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png\",\"datePublished\":\"2019-08-20T16:37:46+00:00\",\"dateModified\":\"2026-02-24T00:32:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2019\\\/08\\\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2019\\\/08\\\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png\",\"width\":1004,\"height\":816},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/08\\\/20\\\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\\\/2 breast cancer families (Contributed by Ms. Inge Lakeman)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/","og_locale":"en_US","og_type":"article","og_title":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog","og_description":"At this moment, risk management for non-BRCA1\/2 breast cancer families is mainly based on family history, calculated by risk prediction algorithms such as BOADICEA. Here, we use a Polygenic Risk Score based on 161 breast cancer associated SNPs, to show the potential clinical utility of this PRS within non-BRCA1\/2 high risk breast cancer families including [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/","og_site_name":"JMG Contact blog","article_published_time":"2019-08-20T16:37:46+00:00","article_modified_time":"2026-02-24T00:32:22+00:00","og_image":[{"width":1004,"height":816,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png","type":"image\/png"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman)","datePublished":"2019-08-20T16:37:46+00:00","dateModified":"2026-02-24T00:32:22+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/"},"wordCount":134,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/","url":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/","name":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1--300x244.png","datePublished":"2019-08-20T16:37:46+00:00","dateModified":"2026-02-24T00:32:22+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2019\/08\/Picture-for-JMG-blog-Manuscript-ID-jmedgenet-2019-106072.R1-.png","width":1004,"height":816},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/08\/20\/addition-of-a-161-snp-polygenic-risk-score-to-family-history-based-risk-prediction-impact-on-clinical-management-in-non-brca1-2-breast-cancer-families\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families (Contributed by Ms. Inge Lakeman)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1320"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1320\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}